JP2015196656A - 一酸化窒素消去剤 - Google Patents
一酸化窒素消去剤 Download PDFInfo
- Publication number
- JP2015196656A JP2015196656A JP2014074646A JP2014074646A JP2015196656A JP 2015196656 A JP2015196656 A JP 2015196656A JP 2014074646 A JP2014074646 A JP 2014074646A JP 2014074646 A JP2014074646 A JP 2014074646A JP 2015196656 A JP2015196656 A JP 2015196656A
- Authority
- JP
- Japan
- Prior art keywords
- nitric oxide
- extract
- eliminating agent
- pharmaceuticals
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title description 102
- 239000000284 extract Substances 0.000 claims abstract description 14
- 229940088382 Nitric oxide scavenger Drugs 0.000 claims description 10
- 240000001307 Myosotis scorpioides Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 206010040070 Septic Shock Diseases 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 6
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 5
- 206010019280 Heart failures Diseases 0.000 abstract description 5
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 5
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 5
- 230000036303 septic shock Effects 0.000 abstract description 5
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 4
- 208000001647 Renal Insufficiency Diseases 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000027866 inflammatory disease Diseases 0.000 abstract description 4
- 201000006370 kidney failure Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 208000017520 skin disease Diseases 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 abstract 1
- 206010013786 Dry skin Diseases 0.000 abstract 1
- 240000009206 Hemerocallis fulva Species 0.000 abstract 1
- 235000002941 Hemerocallis fulva Nutrition 0.000 abstract 1
- 208000026758 coronary atherosclerosis Diseases 0.000 abstract 1
- 230000037336 dry skin Effects 0.000 abstract 1
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000419 plant extract Substances 0.000 description 9
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000722941 Achillea Species 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- BPBUJYBQUBMWDT-VQHVLOKHSA-N (E)-hydroxyimino-[methyl-[3-(methylamino)propyl]amino]-oxidoazanium Chemical compound CNCCCN(C)[N+](\[O-])=N/O BPBUJYBQUBMWDT-VQHVLOKHSA-N 0.000 description 5
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001442129 Myosotis Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 101100278667 Drosophila melanogaster Duox gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- -1 antiseptic Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000002803 fossil fuel Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229940092385 radish extract Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RLNWRDKVJSXXPP-UHFFFAOYSA-N tert-butyl 2-[(2-bromoanilino)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CNC1=CC=CC=C1Br RLNWRDKVJSXXPP-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
具体的には、アキノワスレグサ抽出物を有効成分として含有させて、一酸化窒素消去剤を用いることで上記課題を解決する。本願一酸化窒素消去剤は、そのまま或いは、飲食品、医薬品、又は化粧品に添加して用いることもできる。
一般的には一酸化窒素消去剤の組成物に対して蒸発乾燥分に換算して0.0001〜100質量%が好ましく、特に0.01〜10.0質量%の範囲が最適である。
(1)被検物質の植物抽出物は、アキノワスレグサ(葉及び茎の混合物)、夏枯草(葉及び茎の混合物)、ウラジロガシ(葉)の乾燥物を用いて調製した。各植物原体1gに10倍量の50%エタノールを10g加えて60℃、3時間加熱抽出した。抽出後、ろ過をし、植物原体を取り除いた後、固形蒸発残分が1%になるように蒸留水で希釈した。以上の操作によって、固形蒸発残分が1%になるように調製した植物抽出物を得た。
(2)アスコルビン酸、Trolox(6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸)、BHT(ジブチルヒドロキシトルエン)はDMSO(ジメチルスルホキシド)で溶解させ、全て10 mMの濃度に調製した。
既知の抗酸化物質と植物抽出物のラジカル捕捉能を確認するため、DPPHラジカル捕捉試験を用いて、ラジカル捕捉能の評価を行なった。
(1)MES(2−モルホリノエタンスルホン酸)8.53gをdH2O 100mLで溶解し、400mM MESを調製した。
(2)DPPH(1,1−ジフェニル−2−ピクリルヒドラジル)0.0628gをEtOH 100 mL で溶解し、0.4mM DPPHを調製した。
(3)DPPH:MES:dH2O=4:1:3の割合で混合し、これをDPPH Working Solutionとして調製した。
(4)96穴マイクロプレートに上述の方法で調製した植物抽出物10μLを分注し、DPPH Working solutionを190μL添加し、プレートミキサーで30分振とうさせた。
(5)その後、マイクロプレートリーダーで540nmの吸光度を測定した。測定後、下記のラジカル捕捉率の計算式を用いて算出した。結果は図1に示す。尚、植物抽出物は植物名のみ表記している。
(1)10mM Troloxを調製し、それをDMSOで段階希釈し、標準試薬として用いた。
(2)上記の段階希釈したTroloxの吸光度Ab540の値と濃度から検量線(Y=aX+b、Y=吸光度、X=濃度)を作成した。
(3)その検量線Y=aX+bから、試料のTrolox当量として濃度を算出した。
<式1>
Trolox当量=(測定試料Ab540−b)/a(mM)
既知の抗酸化物質と植物抽出物のNO消去能を確認するため、NOの酸化物であるNO2−を測定することでNO量を測定するGriess法を用いて、NO消去能の評価を行なった。Griess法による測定は、NO2/NO3 Assay Kit−CII(Colorimetric)(同仁化学製)を用いた。NO発生剤として、NOC−7(1−ヒドロキシ−2−オキソ−3−(N−メチル-3―アミノプロピル)−3−メチル−1−トリアゼン)(同仁化学社製)を用い、使用直前に0.1N水酸化ナトリウムのアルカリ溶液で調製した。一酸化窒素供与体として開発されたNOC−7はアルカリ溶液中では安定だが、中性および酸性条件下では一酸化窒素を生成する不安定な化合物(25℃、pH7.4条件下で半減期5分)である。
(2)その後、100μMに調製したNOC−7溶液40μLを添加して、室温で30分反応させた。
(3)反応終了後、Kit中のGriess試薬Aを50μL添加して、続けてGriess試薬Bを50μLずつ添加して10分放置して呈色反応を行った。
(4)マイクロプレートリーダーで540nmの吸光度を測定した。各測定試料における吸光度をS540、試料の代わりに緩衝液とNOC−7のみを混合したコントロールの吸光度をC540、NOC−7を含まないブランクの吸光度をB540として以下の式でNO消去率(%)を算出し、結果を図2に示す。
NO消去率(%)={100×(1−(S540−B540)/(C540−B540)}
尚、実施例では、アキノワスレグサの葉及び茎の50%エタノール抽出物のみを開示しているが、その他の部位、抽出溶媒においても同様の傾向が見られた。
Claims (1)
- ユリ科ワスレグサ属に属するアキノワスレグサの抽出物を含有することを特徴とする一酸化窒素消去剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014074646A JP6333026B2 (ja) | 2014-03-31 | 2014-03-31 | 一酸化窒素消去剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014074646A JP6333026B2 (ja) | 2014-03-31 | 2014-03-31 | 一酸化窒素消去剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015196656A true JP2015196656A (ja) | 2015-11-09 |
JP6333026B2 JP6333026B2 (ja) | 2018-05-30 |
Family
ID=54546592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014074646A Active JP6333026B2 (ja) | 2014-03-31 | 2014-03-31 | 一酸化窒素消去剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6333026B2 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006062998A (ja) * | 2004-08-25 | 2006-03-09 | Ryukyu Bio Resource Kaihatsu:Kk | 睡眠改善剤 |
JP2006143670A (ja) * | 2004-11-22 | 2006-06-08 | Kyoei Kagaku Kogyo Kk | 皮膚外用剤 |
JP2008050326A (ja) * | 2006-08-28 | 2008-03-06 | Kyoei Kagaku Kogyo Kk | 化粧料 |
KR20100037508A (ko) * | 2008-10-01 | 2010-04-09 | 구례군 | 지리산 원추리 추출물을 함유하는 수분감 지속형 화장료조성물 및 그 제조방법 |
-
2014
- 2014-03-31 JP JP2014074646A patent/JP6333026B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006062998A (ja) * | 2004-08-25 | 2006-03-09 | Ryukyu Bio Resource Kaihatsu:Kk | 睡眠改善剤 |
JP2006143670A (ja) * | 2004-11-22 | 2006-06-08 | Kyoei Kagaku Kogyo Kk | 皮膚外用剤 |
JP2008050326A (ja) * | 2006-08-28 | 2008-03-06 | Kyoei Kagaku Kogyo Kk | 化粧料 |
KR20100037508A (ko) * | 2008-10-01 | 2010-04-09 | 구례군 | 지리산 원추리 추출물을 함유하는 수분감 지속형 화장료조성물 및 그 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
JP6333026B2 (ja) | 2018-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3805798B2 (ja) | 化粧料 | |
Baghiani et al. | Antioxidants, Free Radicals Scavenging and Xanthine Oxidase Inhibitory Potentials of Ajuga iva L. Extracts. | |
Macwan et al. | A comparative evaluation of in vitro antioxidant properties of Bamboo Bambusa arundinacea leaves extracts | |
JP2021516669A (ja) | インドセンダン葉抽出物を含む化粧料組成物 | |
JP4866501B2 (ja) | 皮膚外用剤 | |
JP4546790B2 (ja) | 皮膚常在菌を殺菌しない低級脂肪酸生成抑制剤 | |
JP6333026B2 (ja) | 一酸化窒素消去剤 | |
JP4179981B2 (ja) | チオール−s−メチルトランスフェラーゼ阻害剤、口臭発生抑制剤および口臭発生抑制組成物 | |
JP2012031086A (ja) | 抗酸化剤及び化粧料 | |
JP2005263655A (ja) | 抗酸化剤 | |
KR20200064384A (ko) | 약쑥을 함유한 항산화 및 항염증 화장료 조성물 | |
JP2006249035A (ja) | 活性酸素除去剤 | |
KR101416993B1 (ko) | 주름개선용 화장료 조성물 | |
JPH06305978A (ja) | チロシナーゼ阻害剤、美白化粧品および変色防止剤 | |
JP2003335647A (ja) | 消臭剤及びそれを含有する飲食品並びに消臭組成物 | |
JP2005213202A (ja) | 抗酸化剤、抗老化剤及び抗炎症剤、並びに、皮膚化粧料 | |
JP5004045B2 (ja) | 抗菌剤及び抗菌性組成物 | |
JP5557973B2 (ja) | 皮膚外用剤 | |
JP2010018545A (ja) | 活性酸素消去剤、皮膚外用剤、口腔用組成物及び食品 | |
JP4295639B2 (ja) | 抗酸化剤 | |
JP2013224318A (ja) | 活性酸素消去剤、皮膚外用剤、口腔用組成物及び食品 | |
JP5512291B2 (ja) | 皮脂産生抑制剤 | |
JP4886878B2 (ja) | チロシナーゼ活性阻害剤および美白化粧料 | |
JP2018062481A (ja) | アルブチン含有組成物、及び、アルブチンの分解抑制方法 | |
JP2011037851A (ja) | 皮膚美白用組成物、植物抽出皮膚美白組成物、および皮膚美白効果を有する組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180417 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180424 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6333026 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |